when did semaglutide come on the market Medicare's new $50 weight-loss drug program: Who qualifies and what are concerns? Semaglutide for Weight Loss: How

The medical community today agrees that obesity is a chronic disease, it is a serious condition that increases the risk of premature death and can lead to other serious health issues such as heart disease, stroke and diabetes," said Chiquita Brooks-LaSure, administrator for the Centers for Medicare and Medicaid Services, in a call with reporters

Regular monitoring of heart rate and blood pressure is advisable during Wegovy treatment, particularly during dose escalation phases

Noom operates in the GLP-1 telehealth space as of April 2026

, Bacon, A

It belongs to a class of drugs called lipase inhibitors

AstraZeneca and Pfizer compete by leveraging broad pharmaceutical portfolios, formulation expertise, and global distribution networks to advance GLP-1 pipelines with an emphasis on long-term safety, differentiated dosing regimens, and scalable home-use formats